Earnings ·
CG Oncology reported a net loss of $79.1 million, or $(0.90) per share, for the quarter ended June 30, 2026, compared…
CGONCG Oncology, Inc.
CG Oncology reported a net loss of $79.1 million, or $(0.90) per share, for the quarter ended June 30, 2026, compared to a $41.4 million loss in the prior year period. Research and development expenses increased to $54.7 million from $31.3 million, while general and administrative expenses rose to $29.0 million from $17.4 million. The company holds approximately $1.0 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, sufficient to fund operations through 2029. Additionally, CG Oncology filed Amendment No. 2 to its Prospectus under an Open Market Sale Agreement with Jefferies LLC, increasing the amount of common stock available for sale by an additional $500.0 million. The company is a late-stage clinical biopharmaceutical firm developing cretostimogene, an investigational oncolytic immunotherapy for bladder cancer.